Pds Biotechnology Corporation · NASDAQ:PDSB
Pds Biotechnology — Investor Presentation (May 2022)
24 slides from Pds Biotechnology's investor presentation, May 11, 2022
Slide 1: Precision Designed Science For Immunotherapy
Precision Designed Science For Immunotherapy INVESTOR PRESENTATION NASDAQ: PDSB | May 2022
Slide 2: Forward-Looking Statements
2 This presentation contains forward-looking statements about PDS Biotechnology Corporation (“PDSB”), and its businesses, business prospects, strategies and plans, including but not limited to statements regarding anticipated pre-clinical and clinical drug development activities and timelines and ma
Slide 3: Company Overview
1 2 4 5 6 Company Overview Clinical-stage Company developing molecularly targeted immunotherapies to treat cancer and infectious disease Versamune® and Infectimune™ platforms leverage the body’s own defense systems to induce disease-specific killer T-cells and antibodies to combat cancer and infecti
Slide 4: Versamune Oncology Platform
Versamune® Oncology Platform
Slide 5: The PDS Biotech Differentiation
Generate memory T-cells, to enhance durability of response Generate potency without serious systemic side effects Generate the right type and quantity of effective CD8+ killer T-cells 15-30% Success in checkpoint inhibitor treatments due to low CD8+ T-cell response* Versamune® is designed to promote
Slide 6: Versamune Platform Designed to Recruit, Train and Arm T-cells in the Body
References: Gandhapudi SK, et al. 2019. Antigen priming with enantiospecific cationic lipid nanoparticles induces potent antitumor CTL responses through novel induction of a Type I IFN response. J Immunol. 202 (12): 3524-3536. Smalley R umfield C et al. 2020. Immunomodulation to enhance the efficacy
Slide 7: Versamune-based oncology pipeline developed in partnership with immuno-oncology leaders
Combination PDS Biotech Funded Partner Co-Funded Versamune® Platform Versamune®-based oncology pipeline is being developed in partnership with the leaders in immuno oncology PDS0104 (TRP2) TBD Arm 1: CPI naïve 1st line treatment Arm 2: CPI refractory 2nd or 3rd line treatment PDS0101 (HPV16) VERSATI
Slide 8: PDS0101: Lead Asset Designed to treat HPV16-associated cancers
More than 46,0002 patients were estimated to have been diagnosed last year with HPV-associated cancers in the US1,2 HPV vaccination is not expected to impact the rate of HPV-related cancer incidence for decades Existing immunotherapies cost $150,000+ annually per patient1 US HPV-associated cancer in
Slide 9: PDS0101: Triple Combination
0 5 10 15 Median Survival In Patients Naïve Patients Refractory Patients Reference: Strauss J. et al. Phase II evaluation of the triple combination of PDS0101, M9241, and Bintrafusp alfa in patients with HPV 16 positive malignancies. PDS0101: Triple Combination Promising survival of patients with ad
Slide 10: PDS0101: Triple Combo
*These numbers reflect data as of evaluation of 25 patients; numbers will change as more patients undergo evaluation, includes both CPI refractory and naïve patients. PDS0101: Triple Combo Versamune® induced HPV-16 CD8+ killer T-cells 0% 25% 50% 75% HPV-16 Positive HPV-16 Negative Historical Check P
Slide 11: Phase 2: PDS0101 + KEYTRUDA
Phase 2: PDS0101 + KEYTRUDA® Company-sponsored trial for the treatment of HPV16-positive metastatic/recurrent head and neck cancer (VERSATILE-002) Achieved Safety data presented at Head and Neck Symposium Q1 2022 Preliminary efficacy data released; achieved initial efficacy milestone Q1 2022 in Grou
Slide 12: Phase 2: PDS0101 + Chemoradiotherapy
Phase 2: PDS0101 + Chemoradiotherapy Investigator-led trial evaluating the combination in patients with locally advanced cervical cancer (IMMUNOCERV) Timing Preliminary data anticipated late Q3 2022 Indication Treatment of patients with locally advanced cervical cancer–Stages IB3-IVA Clinical Agents
Slide 13: Phase 2: PDS0101 Monotherapy and in Combination with KEYTRUDA
KEYTRUDA®: Cisplatin and radiation therapy PDS0101: Versamune®-based immunotherapy generating HPV-specific CD8+ and CD4+ T-cells 3 Phase 2: PDS0101 Monotherapy and in Comb. with KEYTRUDA® Investigator-led trial evaluating treatments in patients with HPV-associated oropharyngeal cancer with high risk
Slide 14: PDS0102: TARP Antigen
CFA + TARP (1-20) X PDS0102: TARP Antigen Versamune®-induced CD8+ killer T-cells may result in the ability to treat TARP positive AML and prostate cancers Pre-Clinical Optimization Studies1: TARP-Specific T-cell Induction after 2 injections of PDS0102 1 Reference: Wood LV et al, Oncoimmunology, 2016
Slide 15: PDS0103: MUC1 Antigen
Induced a >10-fold number of polyfunctional (highly potent) MUC1 specific CD8+ T-cells PDS0103: MUC1 Antigen Greater quantity and quality of Versamune®-induced CD8+ killer T-cells may result in the ability to treat breast, ovarian, lung, and colon cancers *References: Surveillance Research Program,
Slide 16: Projected Milestones Through 1Q 2023
Projected Milestones Through 1Q 2023* *Based on current enrollment and forecast modeling as of March 2022. Subject to change. 16 1H21 2H21 1Q22 2Q22 3Q22 4Q22 PDS0101 Interim data from HPV-associated cancer trial ASCO - (NCI) Completed enrollment of HPV- associated cancer trial CPI refractory arm (N
Slide 17: Infectimune Infectious Disease Platform
Infectimune™ Infectious Disease Platform
Slide 18: PDS Biotech's Infectimune Pipeline
PDS Biotech’s Infectimune™ Pipeline Developed in partnership with leaders in infectious disease Prevention of tuberculosis PDS0201 (M-tuberculosis) Candidate Indication PC P1 P2 P3 R Partner(s) Universal prevention of influenza PDS Biotech Funded Partner Co-Funded PDS0202 (influenza) PDS0203 (SARS-C
Slide 19: PDS0202: Universal Prevention of Influenza - Neutralization Against Multiple Strains
PDS0202: Universal Prevention of Influenza Provided Effective Neutralization Against Multiple Strains of Flu Viruses in Preclinical Study Reference: Ross T. and Woodward J. et al. evaluation of the PDS0202 (Infectimune™+ COBRA) Universal flu formulation. Average HAI Neutralization Titer Levels Induc
Slide 20: PDS0202: Universal Prevention of Influenza - Protection in Preclinical Study
Reference: Ross T. and Woodward J. et al. evaluation of the PDS0202 (Infectimune™+ COBRA) Universal flu formulation. PDS0202: Universal Prevention of Influenza Provided Protection in Preclinical Study in Keeping Subjects Alive and Healthy Against Challenge with Flu Virus Control High-Dose Flu Protei
Slide 21: Infectimune Pipeline Highlights
20 Infectimune™ Pipeline Highlights License agreement with University of Georgia for proprietary influenza antigensPositive top-line preclinical data announced; effective delivery of flu proteins activate the critical immune signals necessary to generate powerful neutralizing antibody responses to a
Slide 22: PDS Biotech Management
PDS Biotech Management Historical success in the development and commercialization of leading pharmaceutical products Timing Safety data confirmed and released Q4 2021 Preliminary efficacy data anticipated Q1 2022 Frank Bedu-Addo, PHD Chief Executive Officer Senior executive experience with manageme
Slide 23: Company Overview
1 2 4 5 6 Company Overview Clinical-stage Company developing molecularly targeted immunotherapies to treat cancer and infectious disease Versamune® and Infectimune™ platforms leverage the body’s own defense systems to induce disease-specific killer T-cells and antibodies to combat cancer and infecti
Slide 24: Precision Designed Science Investor Presentation
Precision Designed Science INVESTOR PRESENTATIONNASDAQ: PDSB | May 2022